Tideglusib irreversibly inhibits GSK-3 in human neuroblastoma cells and primary neurons in mice, thereby reducing tau phosphorylation levels and preventing apoptosis. Tideglusib(2.5μM) inhibits glutamate-induced glial activation, as evidenced by decreased expression levels of TNF-α and COX-2 in primary astrocytes or microglia in rats. Tideglusib(2.5μM) also has an effective protective effect on cortical neurons against glutamate-induced neuroexcitatory toxicity. The evidence for this conclusion is that the number of Annexin-V positive cells in primary astrocytes or microglia in large Chemicalbook rats is significantly reduced
In vivo study
Tideglusib(50mg/kg) injected into the hippocampus of adult male Wistar rats can significantly reduce the rhodosine-induced inflammatory response and damage to the hippocampus The area has a protective effect. In APP/tau double-transgenic mice, Tideglusib(200mg/kg orally) reduced tau phosphorylation levels, reduced amyloid deposition and patk-associated astrocyte proliferation, protected neurons in the entorhinal cortex and hippocampal CA1 region from death, and prevented memory loss